Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases
- PMID: 6548246
Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases
Abstract
Rifampicin, Clofazimine and D.D.S. have been tried in fifteen active untreated lepromatous cases for a period of two years. Compared to dapsone monotherapy remarkable clinical and bacteriological improvement was observed with this combined therapy with attainment of negative BI in ten cases. Use of this combination therapy is thus advocated to achieve noninfectivity in a shorter period and to prevent emergence of dapsone resistance thereby causing the path of leprosy control before it becomes unmanageable due to dapsone resistance.
Similar articles
-
Comparison of two multidrug regimens in multibacillary leprosy.Indian J Lepr. 1992 Oct-Dec;64(4):501-4. Indian J Lepr. 1992. PMID: 1308526 Clinical Trial.
-
Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.Indian J Lepr. 1984 Jan-Mar;56(1):63-70. Indian J Lepr. 1984. PMID: 6384381
-
Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.Indian J Lepr. 1987 Jan-Mar;59(1):36-43. Indian J Lepr. 1987. PMID: 3611859
-
[Immuno-allergic accidents with rifamipcin].Acta Leprol. 2001-2002;12(2):71-8. Acta Leprol. 2001. PMID: 12136739 Review. French.
-
[Antibacterial chemotherapy in leprosy: principles, objectives and recommendations].Acta Leprol. 1986 Jul-Sep;4(3):355-62. Acta Leprol. 1986. PMID: 3551474 Review. French. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Medical